Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. Differences from Central Serous Chorioretinopathy Academic Article uri icon

Overview

MeSH Major

  • Clinical Trials, Phase I as Topic
  • Medical Oncology
  • Neoplasms

abstract

  • The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series,┬áMEK inhibitors did not cause irreversible loss of vision or serious eye damage.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ophtha.2017.05.038

PubMed ID

  • 28709702

Additional Document Info